万邦医药
(301520)
| 流通市值：9.32亿 | | | 总市值：27.70亿 |
| 流通股本：2242.30万 | | | 总股本：6666.67万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 146,838,210.56 | 71,052,156.02 | 379,090,705.99 | 293,304,171.94 |
| 营业收入 | 146,838,210.56 | 71,052,156.02 | 379,090,705.99 | 293,304,171.94 |
| 利息收入 | 0 | - | 0 | - |
| 已赚保费 | 0 | - | 0 | - |
| 手续费及佣金收入 | 0 | - | 0 | - |
| 二、营业总成本 | 137,088,912.58 | 67,004,139.61 | 319,913,163.19 | 231,528,566.18 |
| 营业成本 | 95,846,446.79 | 48,583,371.84 | 229,050,743.65 | 166,749,224.26 |
| 利息支出 | 0 | - | 0 | - |
| 手续费及佣金支出 | 0 | - | 0 | - |
| 退保金 | 0 | - | 0 | - |
| 赔付支出净额 | 0 | - | 0 | - |
| 提取保险合同准备金净额 | 0 | - | 0 | - |
| 保单红利支出 | 0 | - | 0 | - |
| 分保费用 | 0 | - | 0 | - |
| 税金及附加 | 901,988.21 | 371,004.48 | 1,562,089.71 | 1,155,391.25 |
| 销售费用 | 4,070,649.63 | 1,870,131.71 | 4,878,851.9 | 4,310,502.16 |
| 管理费用 | 13,016,538.49 | 5,787,453.48 | 26,888,628.7 | 18,945,660.65 |
| 研发费用 | 24,006,530.24 | 10,765,309.15 | 60,681,199.45 | 43,048,445.44 |
| 财务费用 | -753,240.78 | -373,131.05 | -3,148,350.22 | -2,680,657.58 |
| 其中:利息费用 | 0 | - | - | 0 |
| 其中:利息收入 | 768,688.47 | 376,411.05 | 3,176,130.46 | 2,701,972.3 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 11,515,386.15 | 5,464,055.56 | 7,034,391.6 | 20,647,025.67 |
| 加:投资收益 | 2,638,364.11 | 2,149,076.26 | 21,155,290.01 | 2,038,467.95 |
| 净敞口套期收益 | 0 | - | 0 | - |
| 汇兑收益 | 0 | - | 0 | - |
| 资产处置收益 | 0 | - | 16,439.76 | 16,439.76 |
| 资产减值损失(新) | -402,055.93 | -709,902.51 | -2,021,480.27 | -1,708,098.38 |
| 信用减值损失(新) | -1,978,197.32 | 345,692.79 | -3,798,567.06 | -2,410,712.43 |
| 其他收益 | 3,661,603.68 | 472,798.25 | 5,476,209.8 | 1,107,792.21 |
| 四、营业利润 | 25,184,398.67 | 11,769,736.76 | 87,039,826.64 | 81,466,520.54 |
| 加:营业外收入 | 7,042.36 | 8,042.09 | 2,507,520.95 | 2,638,315.26 |
| 减:营业外支出 | 50,000 | 50,000 | 50,619.32 | 49,132.58 |
| 五、利润总额 | 25,141,441.03 | 11,727,778.85 | 89,496,728.27 | 84,055,703.22 |
| 减:所得税费用 | -1,669,964.35 | -121,510.2 | 3,966,050.76 | 6,258,223.49 |
| 六、净利润 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 | 77,797,479.73 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 | 77,797,479.73 |
| 终止经营净利润 | 0 | 0 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 | 77,797,479.73 |
| 少数股东损益 | 0 | - | - | - |
| 扣除非经常损益后的净利润 | 12,327,047.7 | 5,358,872.31 | 55,787,750.4 | 55,899,685.1 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.4 | 0.18 | 1.28 | 1.17 |
| (二)稀释每股收益 | 0.4 | 0.18 | 1.28 | 1.17 |
| 八、其他综合收益 | 0 | - | 0 | - |
| 归属于母公司股东的其他综合收益 | 0 | - | - | - |
| 九、综合收益总额 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 | 77,797,479.73 |
| 归属于母公司股东的综合收益总额 | 26,811,405.38 | 11,849,289.05 | 85,530,677.51 | 77,797,479.73 |
| 归属于少数股东的综合收益总额 | 0 | - | - | - |
| 公告日期 | 2025-08-26 | 2025-04-22 | 2025-04-22 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |